Additionally, reduction of the allelic load of non-synonymous or neoantigenic mutations through the acquisition of allelic imbalance was not considered
Advances in Therapy, 36(11), 29862996
Ongoing drug trials are seeking to demonstrate, in the next several years, if GLP-1 drugs are effective at treating and/or reducing rates of obstructive sleep apnea, heart failure, NASH (nonalcoholic steatohepatitis) and MASH (metabolic dysfunction-associated steatohepatitis), chronic kidney disease, peripheral arterial disease, joint replacement, osteoarthritis, Alzheimers, cancer and all-cause mortality
A combinatorial approach to producing sterically stabilized (Stealth) immunoliposomal drugs
This is the most aggressive healing protocol commonly used and should be reserved for significant injuries or post-surgical recovery